Collaboration between Abu Dhabi Biobank and AstraZeneca Enhances Precision Medicine

Post by : Bianca Suleiman

In a significant announcement, Abu Dhabi Biobank, an initiative under the Department of Health – Abu Dhabi in collaboration with M42, has joined forces with AstraZeneca, a leading global biopharmaceutical enterprise, to further the field of precision medicine and clinical research.

This strategic partnership harnesses Abu Dhabi Biobank’s state-of-the-art biobanking capabilities, genomic resources, and comprehensive population health data, while leveraging AstraZeneca’s expertise across vital therapeutic domains, including cardiovascular, renal, metabolic, respiratory, immunology, and oncology sectors. The aim is to translate scientific breakthroughs into actionable healthcare solutions.

Both entities will engage in a variety of strategic initiatives, targeting clinical development, precision medicine, and the generation of real-world evidence. Their collaborative efforts will enhance biomarker discovery, pharmacogenomics, and tailored patient stratification, enabling healthcare providers to gain deeper insights into diseases and customize treatment approaches.

Additionally, the partnership will investigate health economics, regulatory sciences, and rise of digital health technologies and artificial intelligence. These initiatives aspire to bolster data-driven healthcare practices and facilitate the swift transition of research outcomes into clinical settings.

Albarah ElKhani, Chief Operating Officer of Integrated Health Solutions at M42, emphasized that the partnership signifies a mutual ambition to redefine the medical landscape. He pointed out that integrating in-depth population insights from Abu Dhabi Biobank with AstraZeneca’s scientific talent could pave the way for advancements in disease prevention, diagnosis, and treatment for populations in the Middle East.

Sameh ElFangary, Country President for the Gulf and Pakistan at AstraZeneca, remarked that precision medicine should encompass the diversity of global demographics. He indicated that the collaboration aims to identify patients at risk sooner, particularly in cases of rare and difficult-to-diagnose conditions, thus fostering the evolution of personalized healthcare strategies.

This collaboration represents a crucial advancement in Abu Dhabi’s ambition to emerge as a prominent center for biomedical research and innovation in life sciences. By capitalizing on long-term population data and local intelligence, they seek to expedite the journey from research to regulatory endorsement and practical clinical application.